Oct 25 (Reuters) – A type of HIV medicine that stops the
AIDS virus from entering immune system cells could in future be
put to work against cancer in new combination therapies being
developed by drug companies.
Interest in using so-called CCR5 inhibitors to fight tumours
was fuelled last year when U.S. researchers, testing the drugs
on mice, reported a marked reduction in aggressive breast cancer
cells spreading to the animals’ lungs.
LONDON (Reuters) – GlaxoSmithKline’s drug sales in China slumped 61 percent in the third quarter, hit by a bribery scandal that has damaged its ability to market products in the country and pushed some sales into the hands of rivals.
Chief Executive Andrew Witty said GSK’s business in China had suffered most where other drug options were available – as is the case with its top-selling lung medicine Advair, for which AstraZeneca’s Symbicort is an alternative treatment.
LONDON (Reuters) – Europe’s medicines regulator has come out fighting for greater transparency for clinical trials, arguing that its controversial policy to end data secrecy will be “a boon to drug developers”.
The strong defence of greater openness by the boss of the European Medicines Agency (EMA) and colleagues comes as the agency battles a lawsuit from two U.S. drugmakers over its plans to release data on their medicines.